A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.
Learning Objective
After completing this educational activity, you should be able to:
Diagnosis and tailored treatment of menstrual cycle- and menopausal-related mood disorders are key factors in helping women live the lives they want to live.
Learning Objectives
LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
Learning Objectives
After completing this educational activity, you should be able to:
Explore Hereditary Angioedema treatment, emphasizing individualized care, first-line therapeutic options and investigational agents in clinical development.
Learning Objectives
Mood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.
After completing this educational activity, you should be able to:
What is the future of schizophrenia treatment? An in-depth exploration of novel, non-dopaminergic therapies transforming the standard of care for patients with schizophrenia’s positive and negative symptoms.
Learning Objectives
After completing this educational activity, you should be able to:
This educational activity, presented by Dr. Deligiannidis, Dr. Vega, and Dr. Smith, offers clinicians an essential update on perinatal depression (PND), including its pathophysiology, diagnosis, and treatment options. With a focus on the latest research and therapeutic advancements, this session highlights the significant impact of timely diagnosis and the risks of delayed intervention.
Participants will explore the neurobiological underpinnings of PND, including mechanisms such as altered GABAergic neurotransmission and the roles of neuroactive steroids like allopregnanolone. The presentation also reviews evidence-based approaches, covering both traditional antidepressants (SSRIs, SNRIs, TCAs) and innovative treatments like brexanolone and zuranolone. Practical insights on real-world applications, including considerations for the post-COVID era, provide clinicians with actionable knowledge to enhance care for patients affected by PND.
Join us for a dynamic one-hour CME activity on Parkinson’s Disease Psychosis (PDP) with top experts Mark F. Lew, MD, and Jennifer Hui, MD. Unlock the latest best practices for diagnosing PDP and implementing cutting-edge therapies. The session kicks off with a deep dive into Parkinson’s Disease, covering its prevalence, motor and nonmotor symptoms, and the unique challenges of PDP. Next, master the intricacies of recognizing and diagnosing PDP with the newest diagnostic criteria and screening tools. Finally, conquer PDP treatment and management strategies, including behavioral approaches, medication adjustments, and safe antipsychotic options. Plus, gain invaluable insights from the caregiver of a real-world patient with PDP, providing a firsthand perspective on managing this complex condition. Boost your clinical expertise and transform patient care with this essential update on managing Parkinson’s Disease Psychosis.
Delve into the cutting-edge advancements in Facioscapulohumeral Muscular Dystrophy (FSHD) alongside the dynamic duo of Dr. Leo H. Wang and Dr. Maya N. Hatch in this symposium recorded at the 2024 MDA Clinical & Scientific Conference Summit. Positioned as the third most prevalent muscular dystrophy, FSHD stands as a genetic enigma with intricate roots, showcasing a progressive saga of asymmetrical muscle weakness. Initially targeting the facial and shoulder muscles before spreading its grip onto the extremities, this disorder's clinical narrative presents a formidable challenge in quantifying outcomes. It's an imperative moment to unearth dependable and sensitive metrics for clinical trials, navigating the labyrinthine landscape of FSHD. Acquire invaluable insights into mastering daily functionalities, tackling complications head-on, and remain abreast of the latest breakthroughs in establishing rock-solid measures for gauging progress.